Revlimid's 'three-fold' cancer risk added to US label
This article was originally published in Scrip
Executive Summary
The US FDA has posted a warning on its website highlighting data that demonstrate certain cancer patients treated with Celgene's Revlimid (lenalidomide) have an increased risk of developing new types of cancers. It has also updated Revlimid's label with the information.